# GHRP-2 (Pralmorelin): The Potent Second-Generation Growth Hormone Secretagogue — Complete Research Profile
Growth hormone releasing peptide-2 (GHRP-2), also known by its clinical name pralmorelin and research code KP-102, occupies a unique position in the pharmacology of growth hormone secretagogues. Unlike its predecessor GHRP-6, GHRP-2 was engineered for enhanced receptor potency — achieving higher GH pulse amplitude while moving toward a cleaner hormonal profile. Unlike its successor ipamorelin, it retains some off-target activity that makes it valuable for multi-axis hormonal research.
The result is a compound that sits squarely in the middle of the GHRP family: more potent than GHRP-6, less selective than ipamorelin, and the only synthetic GHRP to receive regulatory approval anywhere in the world — approved in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2004 for the clinical diagnosis of growth hormone deficiency.
This article provides a complete, research-oriented profile of GHRP-2: its molecular structure, receptor pharmacology, GH-releasing mechanism, off-target effects, cardioprotective and cytoprotective findings, comparison with related secretagogues, and its unique role in diagnostic endocrinology. All content is for research and educational purposes. GHRP-2 is a research-use-only (RUO) compound not approved for therapeutic use outside Japan's diagnostic indication.
---
What Is GHRP-2? Structure and Basic Pharmacology
GHRP-2 is a synthetic hexapeptide with the amino acid sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂. It was developed by Kaken Pharmaceutical in Japan through systematic modification of earlier GHRPs (specifically improvements on GHRP-6 and GHRP-1 series compounds). The key structural changes from GHRP-6 include substitution of amino acids that reduce ghrelin-mimetic activity at peripheral receptors while maintaining full agonism at pituitary and hypothalamic GHS-R1a.
Molecular characteristics:
- •Molecular weight: 817.9 Da
- •Sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂
- •Class: synthetic GH secretagogue peptide (GHS)
- •Primary receptor: GHS-R1a (ghrelin receptor type 1a)
- •Secondary receptor: CD36 (scavenger receptor)
A comprehensive PubMed drug profile for pralmorelin confirms GHRP-2 is the most potent of the first-generation hexapeptide GHRPs in terms of pituitary GH release per mole, with an ED50 in the sub-nanomolar range in swine models.
---
Mechanism of Action: GHS-R1a Agonism and Signal Transduction
GHRP-2 exerts its primary effects through full agonist activity at the GHS-R1a receptor — the same receptor targeted by endogenous ghrelin. Signal transduction downstream of GHS-R1a involves:
1. Gq/11-coupled phospholipase C activation → inositol 1,4,5-trisphosphate (IP3) production → intracellular Ca²⁺ release
2. Diacylglycerol (DAG) formation → protein kinase C (PKC) activation
3. Voltage-gated Ca²⁺ channel potentiation → amplified somatotroph depolarization
4. Somatostatin inhibition at the hypothalamic level → disinhibition of GH pulse release
The combined effect produces a sharp, pulsatile GH release that mimics — and amplifies — the normal physiological GH secretion pattern. Research into the GHS-R1a receptor pharmacology by PMC demonstrates that GHRP-2 activates these cascades with essentially identical intracellular kinetics to ghrelin itself.
Dual Receptor Mechanism
Beyond GHS-R1a, research has established that GHRPs including GHRP-2 also interact with CD36, a multifunctional scavenger receptor expressed in cardiac muscle, hepatocytes, macrophages, and epithelial cells. This CD36 interaction is largely responsible for the GH-independent cytoprotective effects of GHRP-2 observed in cardiac, hepatic, and gastrointestinal tissues — effects that persist even when GH receptors are blocked or absent.
---
GH-Releasing Potency: How GHRP-2 Compares to Other Secretagogues
One of the most studied questions in GHS research is how the various peptide secretagogues compare in terms of GH release potency, efficacy, and hormonal selectivity. The landmark ipamorelin study by Raun et al. (1998) provides direct head-to-head data:
| Compound | ED50 (nmol/kg iv, swine) | GH Emax (ng/mL plasma) | ACTH/Cortisol Rise | Appetite Effect |
|---|---|---|---|---|
| GHRP-6 | 3.9 ± 1.4 | 74 ± 7 | Significant | Strong (hunger) |
| GHRP-2 | 0.6 (estimated) | 56 ± 6 | Significant | Moderate |
| Ipamorelin | 2.3 ± 0.03 | 65 ± 0.2 | Not significant | Minimal |
Key takeaways from this data:
- •GHRP-2 has the highest potency (lowest ED50) among the three peptides — it takes the least peptide mass to saturate the receptor and drive GH release
- •GHRP-2's Emax is lower than GHRP-6, indicating some efficacy trade-off for the potency gain
- •Both GHRP-2 and GHRP-6 elevate ACTH and cortisol; ipamorelin does not
This selectivity distinction is critical for research design. Studies examining pure GH axis activity benefit from ipamorelin's clean profile. Studies examining cross-axis hormonal interactions (GH + ACTH + prolactin) may use GHRP-2 specifically because of its multi-hormone activity.
---
GHRP-2 in Clinical Diagnostic Endocrinology
The most significant distinction between GHRP-2 and all other GHRPs is its regulatory approval. Kaken Pharmaceutical received approval from Japan's PMDA in October 2004 for pralmorelin (GHRP Kaken 100) as a diagnostic agent for growth hormone deficiency in adults and children over four years old.
The Pralmorelin Stimulation Test
The pralmorelin stimulation test (PST) is an approved provocative test for GH deficiency diagnosis in Japan. The protocol involves IV administration of pralmorelin (2 µg/kg body weight), followed by serial blood sampling for GH measurement at 0, 15, 30, 60, and 90 minutes post-injection.
The diagnostic cutoff established by pharmacological characterization studies (PMID: 15646370) and clinical validation is a peak GH response of ≥15 µg/L to rule out GH deficiency, with values below this threshold indicating probable GHD.
Advantages of the PST over insulin tolerance test (ITT):
- •No risk of severe hypoglycemia
- •Applicable to patients with cardiovascular disease or seizure disorders who cannot receive ITT
- •Reproducible dose-response without insulin-dependent contraindications
- •Rapid test completion (90 minutes vs. 3+ hours for other tests)
Research on KP-102 general pharmacology (PMID: 15646371) documents the robust, reproducible GH secretory response across repeated administration in both pediatric and adult populations.
Intranasal GHRP-2 in Pediatric Research
An interesting research application explored the use of intranasal GHRP-2 sprays for children with GH deficiency. A PMC-indexed study (PMC4219938) found that while intranasal administration successfully increased endogenous GH secretion, it did not translate into statistically significant improvements in linear growth over the study period — illustrating the complexity of GH axis pharmacology and the difference between acute GH pulse amplitude and sustained anabolic signaling.
---
Off-Target Hormonal Effects: ACTH, Cortisol, and Prolactin
GHRP-2 shares with GHRP-6 the property of stimulating release of adrenocorticotropic hormone (ACTH), cortisol, and prolactin alongside GH. This multi-axis activity is mediated primarily through CRF (corticotropin-releasing factor) release from the hypothalamus.
A mechanistic study (PMID: 15645295) demonstrated that the ACTH-releasing activity of GHRP-2 in rats is mediated mainly by CRF release rather than direct ACTH secretagogue activity at the pituitary. This distinguishes GHRP-2's mechanism from some synthetic GHSs that act directly on corticotrophs.
Research implications of multi-axis activity:
- •Studies measuring GH pulse amplitude must account for simultaneous cortisol and prolactin changes
- •Cortisol elevation provides a confounding variable in metabolic studies that is absent with ipamorelin
- •The ACTH/cortisol response may itself have physiological significance in stress response research
- •Multi-axis stimulation may be desirable in some research contexts (HPA axis + somatotropic axis interaction studies)
---
Appetite and Energy Homeostasis Research
GHRP-2 reliably increases food intake and appetite, mimicking a central effect of ghrelin. A human feeding study (PMID: 15699539 / PMC2824650) demonstrated that GHRP-2 infusion increased caloric intake by approximately 35.9% compared to saline control in healthy men, with parallel increases in hunger ratings. This effect is mediated through hypothalamic NPY and AgRP pathways downstream of GHS-R1a.
Key comparison with GHRP-6:
- •GHRP-6 produces intense hunger with pronounced orexigenic effects
- •GHRP-2 produces moderate appetite increase — less pronounced than GHRP-6 but clearly above baseline
- •Ipamorelin produces minimal appetite stimulation
For researchers investigating ghrelin-mimetic pathways in appetite regulation, GHRP-2 offers an intermediate phenotype — stronger orexigenic signal than ipamorelin but more tractable than GHRP-6's robust hunger stimulation.
---
Cytoprotective and Cardioprotective Research
Among the most significant research findings for GHRP-2 are its GH-independent cytoprotective effects — protective actions in cardiac, hepatic, gastrointestinal, and neuronal tissues that operate through CD36 and GHS-R1a signaling, independent of GH release or downstream IGF-1.
A comprehensive PMC review of GHRPs' cytoprotective effects (PMC5392015) synthesized decades of evidence demonstrating that synthetic GHRPs, including GHRP-2, exhibit:
- •Reduction in reactive oxygen species (ROS) production
- •Enhancement of endogenous antioxidant defenses
- •Inhibition of NF-κB-mediated inflammatory signaling
- •Protection against programmed cell death (apoptosis) in ischemia-reperfusion models
- •Preservation of mitochondrial membrane potential under oxidative stress
Cardiac Research
The cardioprotective effects of GHRP-2 have been particularly well-documented. A seminal study (PMID: 11089529) using an isolated, blood-perfused rabbit heart model showed that 14-day pretreatment with GHRP-2 fully prevented diastolic dysfunction following myocardial stunning — with end-diastolic pressure in treated hearts half that of untreated controls after ischemia-reperfusion.
These cardiac effects involve:
- •Ca²⁺ handling stabilization through GHS-R1a–mediated PKC signaling
- •Reduction in cardiac fibrosis markers
- •Improved left ventricular ejection fraction (LVEF) maintenance under stress conditions
- •Direct cardiomyocyte protection via Ca²⁺ channel modulation
A separate study on vascular oxidative stress (PMID: 19819949) in ApoE-knockout atherosclerosis models found that GHRP-2 significantly reduced vascular superoxide production and improved endothelial function, though without reducing macroscopic atherosclerotic plaque burden — indicating anti-oxidant effects that are dissociated from lipid accumulation processes.
Hepatoprotective Effects
GHRP-2 demonstrates robust hepatoprotective activity in inflammatory and toxic liver models. Research published in the American Journal of Physiology demonstrated that GHRP-2 administration prevents liver inflammatory response in endotoxemia (PMID: 17986630), with significant attenuation of:
- •Circulating transaminase levels (ALT, AST)
- •TNF-α production from liver non-parenchymal cells
- •Nitrite/nitrate accumulation (NO overproduction)
- •Liver histological damage scores
The hepatoprotective mechanism appears to operate through direct interaction of GHRP-2 with hepatic non-parenchymal cells (Kupffer cells, sinusoidal endothelial cells) expressing GHS-R1a and CD36, modulating the innate immune response rather than acting through systemic GH/IGF-1 changes.
Anti-Inflammatory Research
GHRP-2's anti-inflammatory activity extends beyond the liver. A study examining GHRP-2 in arthritic rat models (PMID: 15507538) found significant reduction in joint inflammation markers, paw edema, and inflammatory cytokine production. The effect was attributed to ghrelin receptor activation on immune cells directly — adding to the picture of GHRP-2 as an endocrine-immune modulatory compound rather than a simple GH secretagogue.
---
Analgesic and Neuroprotective Research
A less-discussed research angle involves GHRP-2's effects on pain processing and neuroprotection. A PubMed study on GHRP-2 antinociception (PMID: 24607724) demonstrated that GHRP-2 produces antinociceptive effects at the supraspinal level in mice via opioid receptor interaction — a finding that connects the GHS-R1a system to endogenous opioid pathways and raises research questions about GHRPs as probes for pain-GH axis interactions.
The neuroprotective potential of GHRPs is further supported by the cytoprotection review (PMC5392015), which documents protection of neuronal cells under excitotoxic and oxidative stress conditions.
---
GHRP-2 vs. GHRP-6 vs. Ipamorelin: A Researcher's Comparison
Understanding where GHRP-2 fits in the secretagogue landscape requires direct comparison with the two most commonly researched related peptides:
GHRP-6
The original research GHRP. GHRP-6 is the prototype compound from which the entire GHRP family was derived. Compared to GHRP-2:
- •Lower potency at GHS-R1a (higher ED50)
- •Slightly higher Emax in some swine models
- •Stronger orexigenic effect — GHRP-6 produces pronounced hunger that researchers often regard as a confound
- •Same ACTH/cortisol elevation
- •Same general cytoprotective profile
GHRP-6 remains valuable for research specifically targeting the appetite/orexigenic component of ghrelin receptor biology.
See also: GHRP-6 Research Guide on Peptides.SO
Ipamorelin
The "third-generation" pentapeptide GHRP often described as the most selective GH secretagogue. Compared to GHRP-2:
- •Comparable or slightly lower GH Emax
- •No significant ACTH, cortisol, or prolactin elevation — a crucial advantage for pure GH axis research
- •Minimal appetite effect
- •Lower potency (higher ED50) vs. GHRP-2
- •Preferred when multi-axis confounds need to be eliminated
See also: Ipamorelin Research Profile on Peptides.SO
CJC-1295 (GHRH Analog) + GHRP-2 Combinations
A common research paradigm pairs GHRP-2 with a GHRH analog (CJC-1295 with or without DAC) to achieve synergistic GH release. The combination exploits two complementary pathways:
- •GHRH analogs stimulate cAMP/PKA signaling in somatotrophs
- •GHRP-2 activates Gq/Ca²⁺ pathway + inhibits somatostatin
The result is a supra-additive GH pulse that exceeds what either compound produces alone.
See also: CJC-1295 DAC Research Profile on Peptides.SO
---
Pharmacokinetics and Stability
GHRP-2 is a small hexapeptide (817.9 Da) with the following pharmacokinetic characteristics:
- •Half-life: approximately 15–60 minutes in plasma (short, typical of small peptides without protective modifications)
- •Bioavailability: Very low oral bioavailability due to rapid peptidase degradation in the GI tract; primarily used IV or subcutaneous in research settings
- •Intranasal delivery: Some uptake demonstrated in research, with measurable GH responses but lower peak GH vs. parenteral administration
- •Degradation: Proteolytic cleavage at Trp and Phe residues; D-amino acids at positions 1 and 2 provide partial resistance to N-terminal exopeptidases
A research direction worth noting: scientists have synthesized mono-PEGylated GHRP-2, demonstrating that PEGylation extends the half-life significantly while maintaining receptor binding activity — an example of how peptide bioconjugation strategies can extend the utility of short-lived peptides.
See also: Peptide Bioconjugation Strategies: PEGylation and Lipidation on Peptides.SO
---
Research Applications Summary
GHRP-2 finds utility across several research domains:
GH Axis Research:
- •Provocative testing for GH deficiency (gold standard in Japan)
- •Pituitary reserve assessment
- •Age-related GH decline studies
- •GH secretagogue mechanism comparison experiments
Metabolic Research:
- •Appetite regulation and ghrelin pathway studies
- •Energy homeostasis (interaction with NPY, AgRP, melanocortin systems)
- •Body composition and lipolysis research
Cardioprotection Research:
- •Ischemia-reperfusion injury models
- •Cardiac fibrosis studies
- •Left ventricular function under stress
- •Vascular oxidative stress
Hepatology Research:
- •Endotoxemia and sepsis models
- •Inflammatory liver disease models
- •Antioxidant defense systems in hepatic tissue
Immunology and Inflammation:
- •NF-κB pathway modulation
- •Cytokine network analysis (TNF-α, IL-6 suppression)
- •Arthritic/inflammatory joint models
Neuroscience:
- •Pain processing and antinociception studies
- •Neuroprotection under oxidative stress
- •GHS-R1a expression mapping in CNS
---
Purity, Quality, and Research Considerations
For laboratory use, GHRP-2 should meet the following quality benchmarks:
- •Purity: ≥98% by HPLC (reverse-phase analytical HPLC)
- •Mass confirmation: ESI-MS or MALDI-TOF to confirm molecular weight (817.9 Da) and rule out oxidation, deamidation, or truncation products
- •Sterility and endotoxin testing: Critical for in vivo research applications — endotoxin contamination would confound anti-inflammatory studies
When evaluating a supplier's GHRP-2 Certificate of Analysis, verify that HPLC purity is confirmed with a chromatogram showing a single dominant peak. Mass spectrometry data should confirm the expected [M+H]⁺ ion.
See also: How to Read a Peptide Certificate of Analysis on Peptides.SO
---
Regulatory and Research Status
Outside Japan's approved diagnostic indication, GHRP-2 is classified as a research use only (RUO) compound in the United States, European Union, and most other jurisdictions. It is:
- •Not approved for therapeutic use in humans or animals in countries other than Japan (diagnostic indication only)
- •Not classified as a controlled substance in most jurisdictions, though regulations vary and researchers should verify local requirements
- •Subject to anti-doping rules in competitive sports contexts (World Anti-Doping Agency bans GH secretagogues)
All research with GHRP-2 should be conducted under appropriate institutional review and regulatory oversight per local requirements.
---
Conclusion
GHRP-2 (pralmorelin) represents a scientifically validated and clinically approved growth hormone secretagogue that offers a distinctive pharmacological profile: higher receptor potency than GHRP-6, more pronounced multi-axis hormonal activity than ipamorelin, and the unique distinction of regulatory approval for GH deficiency diagnosis in Japan.
Its research value extends well beyond the GH axis. The growing body of evidence for GHRP-2's cardioprotective, hepatoprotective, anti-inflammatory, and neuroprotective effects — operating through both GHS-R1a and CD36 signaling — positions it as a multi-target probe for investigating cytoprotective mechanisms.
For research teams studying GH pulsatility, ghrelin receptor pharmacology, ischemia-reperfusion injury, or hepatic inflammation, GHRP-2 provides a well-characterized, potent tool with an established clinical validation record unmatched by any other synthetic GHRP.
---
References
1. Pralmorelin drug profile — PubMed (PMID: 15230633)
2. GHRP-2 increases food intake in healthy men — PMC (PMC2824650)
3. GHRP-2 increases food intake — PubMed (PMID: 15699539)
4. Pharmacological characteristics of KP-102 (GHRP-2) — PubMed (PMID: 15646370)
5. General pharmacology of KP-102 (GHRP-2) — PubMed (PMID: 15646371)
6. Ipamorelin: the first selective GH secretagogue — PubMed (PMID: 9849822)
7. ACTH releasing activity of GHRP-2 mediated by CRF — PubMed (PMID: 15645295)
8. Intranasal GHRP-2 spray in short children with GHD — PMC (PMC4219938)
9. GHRPs cytoprotective effects — PMC (PMC5392015)
10. GHRP-2 prevents liver inflammatory response in endotoxemia — PubMed (PMID: 17986630)
11. GHRP-2 cardioprotective effect on diastolic dysfunction — PubMed (PMID: 11089529)
12. GHRP-2 reduces vascular oxidative stress — PubMed (PMID: 19819949)
13. GHRP-2 anti-inflammatory effect in arthritic rats — PubMed (PMID: 15507538)
14. GHRP-2 antinociceptive effects via opioid receptor — PubMed (PMID: 24607724)
15. GH secretagogues in hypogonadal males — PMC (PMC7108996)
---
Further Reading:
- •Ipamorelin: The Selective Growth Hormone Secretagogue — Complete Research Profile
- •Ipamorelin vs GHRP-2: Growth Hormone Secretagogue Comparison for Researchers (2026)
- •GHRP-6: The Original Growth Hormone Releasing Peptide — Complete Research Profile
- •GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)
- •Peptide Stack Builder
- •Dosage Chart
---
Disclaimer: GHRP-2 (pralmorelin) is a research-use-only compound except where explicitly approved for diagnostic use. All content in this article is for educational and research purposes only. This article does not constitute medical advice, does not endorse any specific supplier, and should not be interpreted as guidance for human or animal therapeutic use.